GlassScriptPhysician profile
Nathan Kim Plaskey
NPI 1023457116
$7,970.31
in general payments reported to CMS, 2019-2025
35 companies · $940 in 2025
The $940 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,749 · 2020: $1,395 · 2021: $954 · 2022: $879 · 2023: $540 · 2024: $514 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $2,706.80 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $987.73 | 2019-2025 | Cadence, Evos, Maverick |
| Stryker Corporation | $827.94 | 2019-2025 | Variax, Augment Injectable, Sidekick |
| Musculoskeletal Transplant Foundation INC. | $611.16 | 2020 | |
| Bioventus LLC | $387.23 | 2019-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Djo, LLC | $257.73 | 2020-2024 | Cmf |
| Amgen INC. | $231.61 | 2024-2025 | Krystexxa |
| Horizon Therapeutics Plc | $208.50 | 2019-2023 | Krystexxa |
| Osteomed LLC | $174.69 | 2021 | |
| Organogenesis INC. | $161.61 | 2019-2020 | |
| Depuy Synthes Sales INC. | $144.18 | 2019-2025 | Motoband, Hammerlock2 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $127.01 | 2023-2025 | Jublia |
| Melinta Therapeutics, LLC | $120.37 | 2019-2022 | |
| Arthrosurface Incorporated | $118.45 | 2019 | |
| Koya Medical, INC. | $105.64 | 2024 | Dayspring, Koya Medical |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $102.47 | 2022-2025 | |
| Tactile Systems Technology INC | $99.99 | 2019-2020 | |
| Impactortho, INC. | $62.29 | 2024-2025 | |
| Nevro Corp. | $57.94 | 2022-2023 | Senza |
| Paratek Pharmaceuticals, INC. | $57.77 | 2024-2025 | Nuzyra |
| Treace Medical Concepts, INC. | $53.55 | 2025 | |
| Merck Sharp & Dohme LLC | $40.92 | 2019 | |
| Abbott Laboratories | $40.54 | 2023-2025 | Proclaim |
| Arteriocyte Medical Systems, INC. | $37.92 | 2025 | Magellan |
| Access Pro Medical, LLC | $33.05 | 2025 | Matriderm |
| Orthofix Medical, INC. | $31.46 | 2019-2020 | |
| Forthright Medical - Az, LLC | $29.50 | 2024 | |
| Tei Medical INC. | $26.45 | 2019 | |
| Fidia Pharma USA INC. | $21.12 | 2019 | |
| Medartis INC. | $20.28 | 2020 | |
| Crossroads Extremity Systems, LLC | $18.73 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.25 | 2025 | |
| Averitas Pharma INC. | $17.88 | 2025 | Qutenza |
| Abbvie INC. | $14.92 | 2022 | |
| Zimmer Biomet Holdings, INC. | $14.63 | 2024 | Tricera Handpiece |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Plaskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.